Advertisement
Advertisement
U.S. markets close in 1 hour 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Saniona AB (publ) (SANION.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
3.3850-0.0350 (-1.02%)
At close: 05:29PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4200
Open3.4100
Bid3.3500 x 0
Ask3.3900 x 0
Day's Range3.3050 - 3.4200
52 Week Range1.5720 - 10.9400
Volume221,586
Avg. Volume237,490
Market Cap211.176M
Beta (5Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-7.3900
Earnings DateFeb 23, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SANION.ST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Saniona AB’s Nomination Committee for the Annual General Meeting 2023

      PRESS RELEASE November 25, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced the composition of the Nomination Committee for the Annual General Meeting 2023. Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall comprise of three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On Septembe

    • GlobeNewswire

      Saniona publishes its interim report for the third quarter of 2022

      Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue was SEK 12.0 M (7.6 M)Operating profit/loss was SEK 21.8 M (-88.2 M)Net profit/loss was SEK 17.5 M (-93.7 M)Operating profit/loss was SEK -203.1 M (-286.7 M)Net profit/loss was SEK -204.4 M (-281.8 M)Basic earnings/loss per share was SEK 0.28 (-1.50)Basic earnings/loss per share was SEK -3.28 (-4.52)Diluted earnings/loss per share were SEK 0.28 (-1.50)Diluted earnings/loss

    • GlobeNewswire

      Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies

      PRESS RELEASE November 3, 2022 SAN903 has finalized preclinical development and fulfilled other requirements for clinical developmentPotential first-in-class compound offers a new treatment paradigm for inflammatory and fibrotic diseases Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that SAN903 is ready to start the regulatory process for entering Phase 1 clinical trials either by Saniona alone or together with a partner following successful completion of pre

    Advertisement
    Advertisement